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A B S T R A C T
Objective: To evaluate the effect of the universal infant hepatitis B vaccination program on hepatitis B
infection in China.
Methods: In 2006, a survey was conducted in Shandong Province, China, among children aged 1–14
years, 15 years after the introduction of universal infant hepatitis B vaccination. The subjects were
selected by stratiﬁed, multi-stage sampling. Vaccination history was obtained by immunization
certiﬁcate (when available) or parent recall. Hepatitis B surface antigen (HBsAg) and antibodies to HBsAg
(anti-HBs) and core antigen (anti-HBc) were detected by ELISA. Hepatitis B infection was deﬁned as the
presence of HBsAg and/or anti-HBc. The prevalence rates of HBsAg, anti-HBs and hepatitis B infection
obtained in this survey were comparedwith the results of a survey conducted in 1992 (prior to universal
vaccination).
Results: A total of 3738 children aged 1–14 years were included in the ﬁnal analysis. A vaccination
coverage rate of 93% was achieved in 2006. The prevalence rates of HBsAg and hepatitis B infection
decreased from 8% and 46% in the 1992 survey to 1% and 4%, respectively, in the 2006 survey.
Conclusions: Universal hepatitis B vaccination in infants can result in a 90.47% reduction in hepatitis B
infection in children aged 1–14 years.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis B virus (HBV) infection, whichwas highly prevalent in
China, is a main cause of chronic hepatitis, cirrhosis, and
hepatocellular carcinoma.1 In the ﬁrst national hepatitis B
serological survey in 1979, the prevalence rate of hepatitis B
surface antigen (HBsAg) was found to be 8.75%,2 and it was 9.8% in
the second national survey in 1992.3 The results of the third
national survey in 2006 showed that the HBsAg carrier rate among
population groups aged 1–59, 1–4, and 5–14 years had declined to
7.18%, 0.96%, and 2.42%, respectively.4 In China, the hepatitis B
vaccine (HepB) was ﬁrst used in 1987 and was recommended for
infants by the Ministry of Health in 1992. Since then, universal
infant hepatitis B vaccination has been implemented in China.
HepB was freely provided to infants (but with a user fee of about
US$ 1.10) from 2002 and infants have been vaccinatedwithout any
charge since 2005. The vaccination records of elementary school* Corresponding author. Tel.: +86 10 65105905; fax: +86 10 65592401.
E-mail address: lmlee@pumc.edu.cn (L. Li).
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HepB since 2005. Non- and incompletely vaccinated children are
given catch-up vaccinations. Before 1997, 10 mg plasma-derived
HepB were administered to vaccinate newborns delivered by
HBsAg-negative mothers or mothers with no serological check
record. A 30 mg–10mg–10mg plasma-derived HepB schedule was
implemented in newborns delivered by HBsAg carriers. In 1997,
the DNA recombinant vaccine was introduced into China, and the
plasma-derived vaccine was withdrawn from the market in 2000.
Today, 5 mg recombinant yeast vaccine is recommended for
infants, and the HepB vaccination program consists of a ﬁrst dose
within 24 h after birth, followed by further doses at 1 and 6months
of age. Screening of pregnant women for HBsAg is not compulsory.
Shandong Province is located in the eastern part of China,
covers an area of 156 700 km2 (1.63% of the nation), and has a
population of about 93 million (6.92% of the national population).
It has 17 prefectures and 140 urban districts or rural counties.
More than 1 million babies are born in the province each year. In
addition to the national vaccination program, a massive HepB
immunization campaign was carried out in Shandong Province in
2006, in which children aged 1–14 years with incomplete HepBses. Published by Elsevier Ltd. All rights reserved.
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million children received at least one dose of HepB during the
campaign (data provided by Shandong Provincial Center for
Disease Control and Prevention, unpublished). In 1992, the HBsAg
prevalence rate among children aged 1–14 years was 8% in
Shandong Province.5 The next hepatitis B serological survey was
conducted in April 2006, 15 years after the introduction of the
universal infant HepB vaccination, and we performed a provincial
hepatitis B serological survey in Shandong Province on the basis of
this third national survey. Our survey aimed to determine HepB
vaccination coverage and the prevalence rates of HBV markers
among children born after universal hepatitis B vaccination was
instituted, and to compare the results with those of 1992.
2. Materials and methods
2.1. Study population and sample design
In April 2006, we conducted a cross-sectional serological survey
in Shandong Province, China. The target population was children
aged 1–14 years, born after the launch of the universal hepatitis B
vaccination program. The subjects were selected by stratiﬁed,
multi-stage sampling. The 17 prefectures of Shandong Province
were divided into three geographical areas: the eastern area
(Qingdao, Yantai, Weifang, Weihai, and Rizhao prefectures), the
middle area (Jinan, Zibo, Dongying, Laiwu, and Linyi prefectures),
and the western area (Zaozhuang, Jining, Tai-an, Dezhou,
Liaocheng, Binzhou, and Heze prefectures). Survey locations were
selected by means of probability proportional to size (PPS)
sampling techniques. Four survey locations (urban districts or
rural counties) were obtained from each area, and these 12 survey
locations were shown to have similar demographic compositions
to the whole province (Table 1). Three sub-districts in each urban
district, two towns in each rural county, and one resident
commission (village) in each sub-district (town) were selected
randomly. In the selected resident commission (village), all
children aged 1–4 years were interviewed and participants agedTable 1
Demographic composition of the population in the sample locations and the whole
of Shandong Province in China, 2006
Sample locations (%) Whole provincea (%)
Age (years)
1–4 4.62 4.61
5–9 5.42 5.79
10–14 11.96 12.23
15–19 8.92 9.47
20–24 7.36 7.63
25–29 9.98 9.80
30–34 12.10 12.02
35–39 10.81 10.49
40–44 8.86 8.15
45–49 9.10 8.85
50–54 6.31 6.45
55–59 4.57 4.50
Chi-square =0.156, p>0.05
Gender
Male 50.75 50.62
Female 49.25 49.38
Chi-square =0.00068, p>0.05
Residential area
Urban 31.26 24.55
Rural 68.74 75.45
Chi-square =2.43, p>0.05
Geographic location
Eastern 29.96 31.02
Middle 25.19 25.65
Western 44.85 43.33
Chi-square =0.10, p>0.05
a Data source: Tabulation of the 2000 population census of Shandong Province.6.5–14 years were chosen by systematic sampling. If an interviewee
was not contactable or the interview was not permitted by the
parents, the child was replaced by another of the same age and
gender living in the same resident commission (village).
Our survey required 1522 children aged 1–4 years and 2270
children aged 5–14 years to obtain an absolute precision of 0.5%, a
signiﬁcance level a of 0.05 (Za/2 = 1.96), and an estimated
prevalence of HBsAg-positive children of 1% and 1.5%, respectively,
in the two age groups. The design effects for the prevalence rate of
HBsAg were 2.95 and 2.69 among children aged 1–4 and 5–14
years, respectively, obtained using PROC SURVEYFREQ in SAS 9.1.3.
2.2. Data collection and laboratory procedures
Each survey team consisted of three interviewers from the local
center for disease control and prevention. The interviews were
carried out using a standard questionnaire. For a child with no
immunization certiﬁcate, the HepB vaccination history was
registered by parent description.
Blood samples were collected and HBsAg, antibody to hepatitis
B surface antigen (anti-HBs), and antibody to hepatitis B core
antigen (anti-HBc) were detected using ELISA by the laboratory of
the National and Provincial Centers for Disease Control and
Prevention. The kits were provided by Xiamen Xin Chuang
Biotechnology Co., Ltd and Shanghai KeHua Biotechnology Co., Ltd.
2.3. Statistical analysis
We calculated theweighted complete vaccination coverage rate
of HepB and the weighted prevalence rate of HBV markers in
children of different ages, genders, and residential areas. The
complete vaccination coverage rate of HepB was deﬁned as the
percentage of persons receiving three or more doses of HepB, and
HBV infection was deﬁned as the presence of HBsAg and/or anti-
HBc. Weights were created to account for the different selection
probabilities of persons across the sub-districts (towns), resident
commissions (villages), and age groups, and the datawere adjusted
by the age and gender composition of the whole provincial
population.6 The numbers of sub-districts (towns) and resident
commissions (villages) were obtained from the local statistics
bureau and the demographic information for each sub-district
(town) was obtained from the local domiciliary register. In order to
compare the prevalence rates of HBV markers in our study with
those of 1992,5 the children were divided into ﬁve age groups: 1
year and < 2 years, 2 years and <4 years, 4 years and <6 years,
6 years and <10 years, and 10–14 years. PROC SURVEYFREQ in
SAS 9.1.3 was used for all calculations.
2.4. Ethical considerations
The study protocol was approved by the Ethics Committee of
theMedical School of ShandongUniversity and consent documents
were signed by the children’s parents.
3. Results
3.1. Demographic characteristics
A total of 3738 children participated in the survey: 1503
children aged 1–4 years and 2235 children aged 5–14 years. The
gender and geographical distributionswere as follows: 1945males
(52.03%) and 1793 females (47.97%); 1198 (32.05%) from urban
areas and 2540 (67.95%) from rural areas; 1238 (33.12%), 1262
(33.76%), and 1238 (33.12%) from the eastern, middle, and western
areas, respectively. Among the children selected, 15.14% were
replaced by the method mentioned in the Materials and methods.
Table 2
History and coverage of HepB vaccination among children aged 1–14 years by age, gender, and residential area in Shandong Province, China, 2006
Sample size No. of children with different HepB doses Complete coverage rate
Unknown <3 3 % 95% CI
Overall 3738 48 119 3571 92.67 90.91–94.43
Age (years)
1 355 0 7 348 98.87 97.05–100
2 415 0 1 414 99.93 99.81–100
3 391 0 1 390 99.83 99.48–100
4 342 1 0 341 99.92 99.79–100
5 262 0 1 261 99.69 99.10–100
6 243 1 1 241 99.27 98.15–100
7 219 0 2 217 99.36 98.25–100
8 246 2 4 240 98.56 96.31–100
9 283 4 7 272 96.75 93.19–100
10 243 1 6 236 94.93 90.20–99.66
11 201 4 16 181 86.68a 76.90–96.46
12 174 8 20 146 73.69b 61.81–85.56
13 185 12 23 150 72.95b 65.03–80.87
14 179 15 30 134 71.00b 63.26–78.73
Gender
Male 1945 28 59 1858 92.31 89.80–94.81
Female 1793 20 60 1713 93.09 91.60–94.57
Residential area
Urban 1198 32 35 1131 91.94 88.33–95.54
Rural 2540 16 84 2440 92.79 90.66–94.92
Geographic location
Eastern 1238 5 15 1218 97.30 94.43–100
Middle 1262 5 61 1196 89.62c 86.06–93.17
Western 1238 38 43 1157 94.56 91.06–98.07
CI, conﬁdence interval.
a p<0.05 comparing results for children aged 11 years vs. those younger than 8 years.
b p<0.05 comparing results for children older than 11 years vs. those younger than 11 years.
c p< .05 comparing results for children in the middle area vs. those in the eastern area.
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HepB vaccination history was unknown in 48 (1.28%) children.
Of the other 3690 children, 119 (3.18%) had received none or fewer
than three doses of HepB, and 3571 (95.53%) had received three or
more doses. The weighted complete vaccination rate was 92.67%
(95% conﬁdence interval (CI) = 90.91–94.43%) among children
aged 1–14 years in 2006. It was signiﬁcantly lower among children
aged 10–14 years (81.22%, 95% CI = 77.85–84.60%) compared to
those aged 1–9 years (99.10%, 95% CI = 97.96–100.00%). The rates
were not signiﬁcantly different when subjects were grouped
according to gender or residential area (urban or rural area).
However, a signiﬁcantly higher vaccination rate was found among
children from the eastern area compared to those from the middle
area (Table 2).
3.3. Seroprevalence of HBV markers
The weighted prevalence rates of HBsAg, anti-HBc, anti-HBs,
and HBV infection were 1.36% (95% CI = 0.60–2.13%), 4.24% (95%
CI = 2.58–5.91%), 68.23% (95% CI = 65.68–70.78%), and 4.35% (95%
CI = 2.82–5.88%), respectively, among children aged 1–14 years
(Table 3). The HBsAg prevalence rate was lowest in 1-year-old
children (0.73%, 95% CI = 0–1.70%) and highest among those aged
10–14 years (1.93%, 95% CI = 0.78–3.07%), but the difference was
not signiﬁcant. The anti-HBs prevalence rate in 1-year-olds was
signiﬁcantly higher than that for the other age groups. The highest
prevalence rates of anti-HBc and HBV infection were observed in
children aged 10–14 years. There was no signiﬁcant difference in
the prevalence rates of these markers for different genders and
living conditions (urban or rural area). However, the children from
the western area had a signiﬁcantly higher HBsAg rate than those
from the eastern area (2.17% vs. 0.62%) (Table 3). Even amongchildren who had received three or more doses of HepB during
infancy, the anti-HBc prevalence rate was still signiﬁcantly higher
in the 10–14 years age group than in the other age groups (Table
4).
In comparison with the 1992 survey,5 the HBsAg prevalence
rate among children aged 1–14 years decreased by 83.00% (from8%
to 1.36%), the HBV infection rate decreased by 90.47% (from 45.63%
to 4.35%), and the anti-HBs rate increased by 257.04% (from 19.11%
to 68.23%). Such trends were observed across all age groups
(Figures 1–3).
4. Discussion
HBV was considered to be highly endemic in China. As HBV
infection usually occurs during infancy or early childhood when it
is most likely to become chronic, the vaccination of infants
beginning at birth is the key strategy in preventing chronic HBV
infection. Universal infant hepatitis B vaccination was launched in
China in 1992 and, since then, great efforts have been made to
achieve a high HepB coverage among children. Shandong Province
has the second largest population in China, with more than 1
million babies born every year. Our study showed that the
complete HepB vaccination coverage rate among children aged 1–
14 years in Shandong Province in 2006 had reached 92.67%, similar
to the average HepB coverage reported in eastern China.7 Only 10
of 2008 preschool interviewees had incomplete HepB vaccination,
while the complete vaccination coverage rate among children aged
10–14 years was very low (81.22%). This suggests that immuniza-
tion certiﬁcate checks and catch-up vaccinations should be
extended to junior middle school children. A lower complete
hepatitis B vaccination rate was observed among children from the
middle area of the province, which should be further investigated.
Since immunization records were not well kept during the 1990 s,
Table 3
Prevalence rate of HBV markers among children aged 1–14 years by age, gender, and residential areas in Shandong Province, China, 2006
Sample size HBsAg Anti-HBs Anti-HBc HBV
% 95% CI % 95% CI % 95% CI % 95% CI
Overall 3738 1.36 0.60–2.13 68.23 65.68–70.78 4.24 2.58–5.91 4.35 2.82–5.88
Age (years)
1 355 0.73 0–1.70 81.92a 75.89–87.94 1.03 0–2.72 1.43 0–3.25
2–3 806 1.17 0–2.64 71.31 67.10–75.52 2.52 0–6.12 2.52 0–6.12
4–5 604 1.05 0–2.42 65.50 57.46–73.54 1.86 0–3.77 1.87 0–3.77
6–9 991 1.05 0.31–1.78 70.06 65.29–74.83 2.55 1.54–3.56 2.77 2.05–3.48
10–14 982 1.93 0.78–3.07 64.18 60.16–68.20 7.81b 5.34–10.28 7.86b 5.40–10.32
Gender
Male 1945 1.61 0.67–2.55 67.16 64.06–70.26 4.46 3.05–5.87 4.50 3.09–5.91
Female 1793 1.08 0.36–1.8 69.47 65.45–73.49 4.00 1.45–6.54 4.18 1.92–6.45
Residential area
Urban 1198 1.65 0.43–2.88 65.55 60.94–70.16 3.99 3.03–4.95 4.13 3.07–5.19
Rural 2540 1.31 0.36–2.26 68.68 65.53–71.83 4.29 2.19–6.39 4.39 2.45–6.32
Geographic location
Eastern 1238 0.62 0.29–0.94 71.51 63.76–79.26 1.7 0–3.72 1.71 0–3.72
Middle 1262 1.02 0–2.67 69.13 64.73–73.53 3.61 2.69–4.53 3.66 2.84–4.48
Western 1238 2.17c 1.08–3.26 65.48 60.34–70.62 6.29 1.73–10.86 6.52 2.45–10.59
HBsAg, hepatitis B surface antigen; anti-HBs, antibodies to hepatitis B surface antigen; anti-HBc, antibodies to hepatitis B core antigen; HBV, hepatitis B virus; CI, conﬁdence
interval.
a p<0.05 comparing results for children aged 1 year vs. those aged 2–14 years.
b p<0.05 comparing results for children aged 10–14 years vs. those aged 1 year, 4–5 years and 6–9 years.
c p<0.05 comparing results for children in the western area vs. those in the eastern area.
Table 4
Prevalence rate of HBV markers among children who received three doses of HepB during infancy in Shandong Province, China, 2006
Age (years) Sample size HBsAg Anti-HBc Anti-HBs
Positive number % 95% CI Positive number % 95% CI Positive number % 95% CI
1 346 2 0.74 0–1.73 5 1.05 0–2.78 295 81.88a 75.64–88.12
2–3 796 6 1.19 0–2.68 13 2.56 0–6.21 594 71.45 67.47–75.42
4–5 592 4 1.07 0–2.45 11 1.9 0–3.82 414 65.45 57.33–73.56
6–9 912 6 1.14 0.38–1.89 17 2.56 1.29–3.84 646 69.98 65.12–74.84
10–14 735 19 2.38 0.79–3.97 48 8.72b 5.29–12.16 476 64.82 59.54–70.08
Total 3381 37 1.47 0.63–2.32 94 4.17 2.19–6.16 2425 68.82 66.23–71.4
HBsAg, hepatitis B surface antigen; anti-HBc, antibodies to hepatitis B core antigen; anti-HBs, antibodies to hepatitis B surface antigen; CI, conﬁdence interval.
a p<0.05 comparing results for children aged 1 year and the other four age groups.
b p<0.05 comparing results for children aged 10–14 years vs. those aged 1 year, 4–5 years and 6–9 years.
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obtained by interviewing the child’s parents. Uncertain answers
were classiﬁed as unknown immunization history, which might
partly have contributed to the low HepB coverage among children
aged >10 years. Recall bias was minimized by independent
interviews with the parents.
In 1992, when HepB was ﬁrst recommended in infants, an HBV
serological survey was conducted in Shandong Province based on
the second national survey. Our survey was conducted in 2006, 15Figure 1. Comparison of the age-speciﬁc prevalence rate of HBsAg among children
aged 1–14 years in 1992 and 2006.years after universal infant hepatitis B vaccination was instituted.
There were some differences between the two surveys. One
thousand two hundred and twenty-ﬁve children aged 1–14 years
were selected by two-stage sampling from seven urban districts or
rural counties in the 1992 survey,while 3738 childrenwere selected
by three-stage sampling from 12 districts or counties in the 2006
survey.Markers for HBsAg, anti-HBs, and anti-HBcwere detected in
both surveys, but they were detected by solid phase radio-
immunoassay (SPRA) in the 1992 survey and by ELISA in theFigure 2. Comparison of the age-speciﬁc HBV infection rate among children aged 1–
14 years in 1992 and 2006. In the 1992 survey,5 HBV infection was deﬁned as the
presence of either HBsAg, anti-HBc, or anti-HBs.
Figure 3. Comparison of the age-speciﬁc prevalence rate of anti-HBs among
children aged 1–14 years in 1992 and 2006.
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for the two surveys because the rate was not reported in the 1992
survey. HBV infection was deﬁned as the presence of HBsAg, anti-
HBs, or anti-HBc in the 1992 survey, and subsequently as the
presence of HBsAg or anti-HBc because of comprehensive vaccina-
tionwithHepBafter1992.Despite thesedifferences, the twosurveys
demonstrated a decline in the HBV infection rate after the
implementation of universal infant hepatitis B vaccination, because
the trends could not be explained by the differences in survey
methods (Figures 1–3). Similar results have been reported in other
countries and areas.8–11 The incidence of hepatitis B reported by the
National Notiﬁable Infectious Disease Reporting System also
declined from 14.5/100 000 to 1.82/100 000 among children aged
0–4 years, and from 21.30/100 000 to 4.51/100 000 among those
aged5–14years inShandongProvinceduring thesameperiod.Other
public healthmeasures, such as the enforcement of blood screening
and implementation of safe injection practices, were not investi-
gated in our study, but may also have played some part in these
achievements. However, the high HepB coverage undoubtedly
played the most important role in the decrease in HBV infections
among children, because maternal–neonatal transmission is the
major route for chronic HBV infection in HBV endemic areas.
Our data showed that children aged 1 year had a signiﬁcantly
higher prevalence of anti-HBs than those older than 1 year. No
signiﬁcant difference in HBsAg prevalence was found between age
groups, while anti-HBc prevalence in the group aged 10–14 years
was signiﬁcantly higher than that in children aged <10 years
(Table 3). This could potentially be explained by lower HepB
coverage and waning anti-HBs among older children.12–16 Even
among childrenwho received three doses of HepB during infancy, a
signiﬁcantly higher anti-HBc prevalence and similar HBsAg
prevalence were found in the group aged 10–14 years, which is
comparable to the previous observation.12,16
In recent years, many researchers have focused on the need for
HepB booster injections. Themajority of results have indicated that
the protection induced by HepB primary immunization may
persist for 10–18 years,13,17–19 and some results have suggested
that a booster dose, given 18 years after the ﬁrst injection or even
earlier, is necessary to retain immunity.20 Although a number of
studies have identiﬁed the persistence of anti-HBs, the resultswere
not well accepted because different vaccine products and different
immunization schedules were used.17–20 Moreover, some
researchers noted geographic and ethnic variations in the long-
term efﬁcacy and immunogenicity of HepB.18 It is necessary to
initiate a nationwide and well-controlled epidemiological inves-
tigation in China.
In our study, 37 children with complete hepatitis B vaccination
in infancy were HBsAg-positive. Among them, only one child
described a history of an HBsAg carrier mother in the ques-
tionnaire. This is quite different from observations in Taiwan8 andUzbekistan,21 where most HBsAg-positive children were born to
HBV-infected mothers. One reason may be that the screening of
pregnant women for HBsAg is not compulsory in China, so that
some of them were not aware of their HBV infection until clinical
diagnosis. Another explanation is that parents may deny their HBV
carrier status to avoid potential discrimination in the community.
A third possibility is immuno-tolerance towards the HBV vaccine
or infection with vaccine escape variants.8,12,22
In the 2006 study, we selected subjects from a population
register provided by the local government. During the investiga-
tional period, some children moved to other locations or traveled
with their parents. This was the main reason for the high non-
responder rate (15%) in our study. Very few parents refused to
permit interviews or to provide blood samples. To ensure a
sufﬁcient sample size, we replaced children lost to follow-up with
children of the same age and gender living in the same resident
commission (village). We were not able to compare the
characteristics of the children lost to follow-up with those of
the children who replaced them. Considering the main reason for
non-response was the ﬂoating population rather than refusal to
participate in the investigation, we believe that the replacement of
subjects would have had very little impact on our results.
In conclusion, our study demonstrates a high complete
hepatitis B vaccination rate among children born after the
introduction of universal infant vaccination in Shandong Province.
The HBV infection rate among children declined by about 90%
following 15 years of universal HepB vaccination in infancy. An
interesting ﬁnding is that the risk of HBV infection, but not the risk
of being an HBsAg carrier, increased 10 or more years after HepB
primary immunization. Further research should be carried out on
the long-term efﬁcacy and immunogenicity of HepB vaccination in
China.
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